Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
421.73 K
Value Traded
3.69 M
Short % Float
6.54%
+2.3%Week
-43.94%1 Month
-18.85%3 Month
-18.85%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
332.63 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
289.62 M
Total Shares
18.93 M
Float Shares
12.09 M
Insiders
36.14%
Institutions
25.91%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SCTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Scribe Therapeutics Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Scribe Therapeutics Inc. Common Stock
12Total events
2Upcoming
1Tier-1 (high impact)
2026 to 2029Coverage
Upcoming catalysts 2
Event history 9
●IpoCorporate
Pricing of upsized initial public offering of 8,580,000 shares at $15.00 per share
▲Trial InitiationSTX-1150Trial
Initiated first-in-human Phase 1 trial of STX-1150 in Australia
elevated LDL-C and increased risk of ASCVDsource ↗
▲Oral PresentationSTX-1150Presentation
Presented late-breaking data at EAS Congress supporting STX-1150
LDL-C loweringsource ↗
Past FDA Catalysts and PDUFA Decisions
How SCTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every SCTX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Aghazadeh BehzadDirector, 10% Owner, See Remarks | Buy | 7,905 3,088,888 held | $18.25 | 07/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SCTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SCTX for Q2 2026. | ||||
SCTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SCTX ranks across every disease it competes in
Competitive Position is a premium feature
See how SCTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSCTX News
-SCTX
Sep 2, 2026Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Scribe Therapeutics reported its Q2 2026 financial results, highlighting the initiation of a Phase 1 trial for STX-1150, a novel LDL-C lowering therapy. The company secured over $25 million in grants from CIRM and raised approximately $155.5 million through an IPO. Despite a net loss of $6.5 million, Scribe is well-funded into 2029 and is advancing its cardiometabolic pipeline.
Read more →-SCTX
Sep 1, 2026▼ -5%on this newsshared move
Scribe Therapeutics to Participate in Upcoming Investor Conferences
Scribe Therapeutics Inc. will participate in several upcoming investor conferences, showcasing its innovative CRISPR technologies aimed at disease prevention and therapeutic intervention. CEO Benjamin Oakes will engage in discussions at the Wells Fargo Healthcare Conference and the H.C. Wainwright Global Investment Conference, while CFO David Parrot will present at the Cell & Gene Meeting on the Mesa. The company aims to improve cardiovascular health through its lead candidate, STX-1150.
Read more →-SCTX
Jul 27, 2026Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
Scribe Therapeutics has successfully closed its initial public offering, raising approximately $155.51 million. The offering included the full exercise of underwriters' option to purchase additional shares, totaling 9,867,000 shares sold at $15.00 each. Additionally, Scribe closed a concurrent private placement of 500,000 shares to Sanofi. The company aims to develop CRISPR-based genetic medicines.
Read more →-SCTX
Jul 24, 2026Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
Scribe Therapeutics has announced the pricing of its upsized initial public offering, offering 8,580,000 shares at $15.00 each, aiming for gross proceeds of $128.7 million. The shares will begin trading on Nasdaq under the symbol 'SCTX' on July 24, 2026. Additionally, a concurrent private placement of 500,000 shares to Sanofi is also set to close on July 27, 2026.
Read more →-SCTX
Jun 18, 2026Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
Scribe Therapeutics has been awarded more than $25 million by the California Institute for Regenerative Medicine (CIRM) to advance two preclinical CRISPR-based therapies, STX-1200 and STX-1400. These therapies target cardiovascular and metabolic diseases, aiming to provide durable solutions for conditions like elevated Lp(a) and triglycerides. The funding supports Scribe's commitment to developing innovative genetic medicines.
Read more →-SCTX
May 28, 2026Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose
Scribe Therapeutics presented promising preclinical data for STX-1150, an epigenetic silencing therapy targeting PCSK9 to achieve long-lasting LDL-C reduction. The therapy demonstrated up to 90% PCSK9 reduction and over 68% LDL-C lowering in non-human primates, with effects lasting more than 22 months. Currently in Phase 1 trials, STX-1150 aims to provide a durable solution for patients with elevated LDL-C and cardiovascular risk.
Read more →-SCTX
May 21, 2026Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
Scribe Therapeutics has received clearance from the Australian TGA to begin a first-in-human clinical study of STX-1150, aimed at reducing LDL-C levels in patients with hypercholesterolemia. This novel therapy utilizes an epigenetic silencing strategy targeting PCSK9, potentially offering a long-lasting solution to manage cardiovascular risks. The Phase 1 trial will evaluate safety and efficacy in up to 64 participants across Australia and New Zealand.
Read more →-SCTX
May 18, 2026Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
Scribe Therapeutics presented preclinical data at ASGCT 2026, showcasing their innovative allosteric ELXR epigenetic silencer. The findings indicate significant improvements in the potency and specificity of their engineered CRISPR technologies for gene editing and epigenetic silencing. The research emphasizes the mechanistic insights and AI-based predictive modeling that support these advancements.
Read more →-SCTX
Apr 30, 2026Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
Scribe Therapeutics will present its engineered CRISPR technologies and the preclinical data for its STX-1150 therapy at the upcoming ASGCT and EAS Congresses. The presentations will demonstrate advancements in CRISPR gene editing and epigenetic silencing, with a focus on improving outcomes for cardiometabolic diseases. The company aims to reshape treatment approaches through innovative genetic medicines.
Read more →About Scribe Therapeutics Inc. Common Stock
Headquarters1150 MARINA VILLAGE PKWY, ALAMEDA, CA, 94501
BIOPHARMAWATCH ELITE PLUS
Trade the next SCTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime